Parallel Bio, a cutting-edge biotech company, has announced the appointment of Ari Gesher as its first Head of Technology. Gesher, an experienced technologist with a background at Insight M and Palantir, will spearhead the development of advanced AI and robotics infrastructure to scale Parallel Bio’s immune organoid platform for drug discovery. This platform uses 3D self-assembling models, known as organoids, to replicate human immune systems and predict the efficacy and safety of new immunotherapies. Gesher’s role will focus on automating lab processes, developing software, and building predictive disease models, significantly enhancing the company’s capabilities in drug discovery. Parallel Bio’s innovative approach, exemplified by their new commercial application, ‘Clinical Trial in a Dish’, aims to overcome the high failure rates of traditional animal models and push the boundaries of medical science.

Biotechnology, Artificial Intelligence, Pharmaceuticals,United States